Merck KGaA shares rise 1.7% after HSBC upgrades stock to Buy
Merck KGaA (NYSE:MRK) shares rose 1. 7% to €141.
Yahoo3 days agoDHR
Is Danaher Stock Underperforming the Nasdaq?
Danaher has underperformed the Nasdaq over the past year, but analysts are highly optimistic about the stock’s prospects.
Yahoo4 days agoDHR
Jim Cramer Calls BillionToOne (BLLN) a “Pretty Darn Good Company”
When a caller asked for the Mad Money host’s take on BillionToOne, Inc. (NASDAQ:BLLN) during the lightning round on August 26, Jim Cramer commented: You know, we did a big piece on this, and we decided, you know, it’s a pretty darn good company. I know it’s expensive, but you know what? Look, genetic diagnostic, […]
Yahoo7 days agoDHR
Why Danaher (DHR) Remains a Healthcare Compounder to Watch
Aristotle Capital Management, LLC, an investment management company, released its “Value Equity Fund” Q2 2026 investor letter. A copy of the letter can be downloaded here. The Fund delivered a 4.32% total return in Q2 2026, underperforming the 13.87% gain for the Russell 1000 Value Index and the 15.20% return for the S&P 500, while […]
Yahoo7 days agoDHR
Why Is Avantor (AVTR) Up 5.4% Since Last Earnings Report?
Avantor (AVTR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Yahoo7 days agoDHR
3 Industrials Stocks with Questionable Fundamentals
Even if they go mostly unnoticed, industrial businesses are the backbone of our country. But they are at the whim of volatile macroeconomic factors that influence capital spending (like interest rates), and the market seems convinced that demand will slow. Due to this bearish outlook, the industry has tumbled by 2.5% over the past six months. This performance is a far cry from the S&P 500’s 10.8% ascent.
Yahoo9 days agoDHR
Danaher Rides on Strength in Biotechnology Segment: Will It Sustain?
DHR's Biotechnology segment grows as China demand, bioprocessing and improving discovery markets offset regional headwinds.
Yahoo10 days agoDHR
Could Danaher Corporation (DHR)’s Bioprocessing Recovery Give Bio-Rad Laboratories (BIO) Stock a Boost?
When biopharmaceutical suppliers report earnings, ripples move fast across the sector. On July 21, Danaher Corporation (NYSE:DHR) reported its Q2 2026 results. While the life sciences giant continues to lead in financial scale, its bioprocessing unit missed expectations, signaling continued softness in broader biopharma demand. The news hit European supplier Sartorius AG, which traded lower […]
Yahoo21 days agoDHR
3 Large-Cap Stocks We Find Risky
Large-cap stocks are known for their staying power and ability to weather market storms better than smaller competitors. However, their sheer size makes it more challenging to maintain high growth rates as they’ve already captured significant portions of their markets.
Yahoo22 days agoDHR
Integrated DNA Technologies Scientists Set New Performance Benchmark for CRISPR Off-Target Nomination
CORALVILLE, Iowa, August 11, 2026--Research shows IDT's UNCOVERseq™ achieved the strongest combined sensitivity and precision among evaluated CRISPR off-target nomination methods.
Yahoo24 days agoDHR
Thermo Fisher (TMO) vs Danaher (DHR): Which Life Sciences Stock Looks Better Positioned?
Thermo Fisher Scientific Inc. (NYSE:TMO) and Danaher Corporation (NYSE:DHR) are two of the world’s largest life sciences tools companies, making them natural competitors for investors looking to capitalize on a recovery in pharmaceutical and biotechnology research spending. Both companies delivered better-than-expected second-quarter results, but while Thermo Fisher (NYSE:TMO) raised guidance on broad-based demand improvement, Danaher’s […]
Yahoo25 days agoDHR
Here's How ABT Broadens Diagnostics Growth Base With Oncology Expansion
Abbott broadens Diagnostics growth with Exact Sciences, as Cancer Diagnostics gains and resilient routine testing offset respiratory weakness.
Yahoo28 days agoDHR
Major Acquisition Alert: Julie A. Sawyer Montgomery Acquires $1.93M In Danaher Stock Options
A noteworthy insider acquisition was disclosed on August 6, as Montgomery, Executive Vice President at Danaher (NYSE:DHR), reported the acquisition of stock options for 245,701 shares. What Happened: A Form 4 filing
Benzinga28 days agoDHR
Witness A Substantial Acquisition As Christopher Bouda Acquires $96K In Danaher Stock Options
In a new SEC filing on August 6, it was unveiled that Bouda, VP at Danaher (NYSE:DHR), acquired stock options for 12,286 shares. What Happened: Bouda, VP at Danaher, engaged in a derivative transaction according to a
Benzinga28 days agoDHR
Matthew E Gugino Makes Strategic Play: Invests $654K In Danaher Stock Options
A substantial acquisition of company stock options by Matthew E Gugino, EVP & Chief Financial Officer at Danaher (NYSE:DHR) was reported on August 6, based on a new SEC filing. What Happened: Gugino, EVP & Chief
Benzinga28 days agoDHR